Published by Iain Gilbert on 21st June 2022
(Sharecast News) - Drugmaker AstraZeneca has received positive high-level results from an interim analysis of its NEURO-TTRansform Phase III trial on eplontersen, the group's hereditary transthyretin-mediated amyloid polyneuropathy drug candidate.
URL: http://www.digitallook.com/dl/news/story/32763003/...